FDA's August 5 device-fee meeting will shape how prosthetic technologies reach patients

The Food and Drug Administration will hold a public meeting on August 5 about the next version of the Medical Device User Fee Amendments, the agreement that helps fund and set performance goals for the agency’s review of medical-device applications.

That sounds distant from everyday prosthetic care. It is not.

The agreement will influence how the FDA staffs device reviews, measures review time, communicates with manufacturers, handles new evidence, and reports whether the medical-device program is meeting its commitments. Those choices can affect how quickly new prosthetic components, control systems, sensors, interfaces, and related rehabilitation technologies move from development into lawful U.S. distribution.

What MDUFA is

Congress allows the FDA to collect fees from medical-device companies when they submit many types of applications. The agency uses that revenue alongside congressional funding to support the review program.

The current authority expires September 30, 2027. The FDA, device industry, and public stakeholders are now working on recommendations for the program covering fiscal years 2028 through 2032.

The August 5 meeting is the final scheduled public meeting in that reauthorization process. The FDA says written public comments will also be accepted for 30 days after the recommendations are published.

Why review policy matters to prosthetic users

A faster review is not automatically a better review, and a slower review is not automatically safer. What matters is whether the system can evaluate evidence efficiently without lowering the bar for safety, durability, cybersecurity, usability, and real-world performance.

For prosthetic users, important questions include:

• whether reviewers have enough specialized engineering and clinical expertise
• how the FDA evaluates software-driven and connected components
• whether review goals account for updates to devices already in use
• how patient-reported experience is incorporated
• whether small manufacturers and novel technologies can navigate the process without avoidable delay
• how clearly the agency explains post-market problems and corrective actions

These issues are especially relevant as more prosthetic systems combine mechanical components with batteries, embedded software, wireless connectivity, pattern-recognition controls, and cloud-connected services.

What the meeting will not decide

The meeting will not determine whether Medicare or private insurance covers a particular prosthesis. FDA authorization and insurance coverage are separate systems.

FDA review asks whether a device may legally enter or remain on the market under the applicable pathway. Coverage decisions ask whether a payer will pay for it for a particular patient under a particular policy.

A device can clear FDA review and still face limited coverage. A coverage policy can also change without any new FDA decision.

How to follow it

The FDA meeting is scheduled for August 5 from 10 a.m. to 3 p.m. Eastern time and includes a virtual option. The agency’s event page links to the webcast and meeting materials.

People who want to comment should focus on concrete system-level effects: review delays, communication failures, gaps in patient input, post-market reporting problems, cybersecurity expectations, or barriers that disproportionately affect users of specialized devices.

The useful question is not whether device review should be “faster” or “stricter” in the abstract. It is whether the next agreement gives the FDA enough resources, expertise, transparency, and accountability to make timely decisions that patients can trust.

---

Amputee News does not provide individualized medical, legal, regulatory, or insurance advice. FDA authorization does not guarantee insurance coverage, and coverage policies vary by payer and patient circumstances.